IVA

Inventiva SA (IVA) is a clinical-stage biopharmaceutical firm based in Daix, France, focused on pioneering oral small molecule therapies for high unmet medical conditions, notably non-alcoholic steatohepatitis (NASH) and mucopolysaccharidosis (MPS). With a strong pipeline of proprietary drug candidates, the company is dedicated to tackling complex metabolic and rare diseases, positioning itself as a significant contributor to advancements in the biopharmaceutical industry. As it progresses toward pivotal clinical trials, Inventiva aims to enhance patient outcomes, highlighting its potential for substantial impact and value creation in the biotechnology sector.